BCAX
Bicara Therapeutics Inc. Common Stock (BCAX) Risks & Opportunities Analysis (2026)
Overall Score
Financial Strength
BCAX maintains a very strong liquidity position with a current ratio of 11.6x and cash ratio of 2.22x.
Balance sheet leverage remains minimal, with debt-to-equity at 0.0025x and debt-to-assets at 0.23%.
Net debt remains modest relative to EBITDA at 0.52x, supporting near-term solvency.
Profitability
Trailing margins remain deeply negative, with EBITDA margin, operating margin, pretax margin, and net margin all at 0 or below.
Returns remain sharply negative, including ROA of -36.2%, ROE of -41.5%, and ROIC of -43.0%.
Earnings and cash flow remain negative, with free cash flow yield at -8.5% and operating cash flow yield at -11.1%.
Valuation
The company screens at a low EV/EBITDA multiple of -8.1x and price-to-free-cash-flow of -11.8x, but these are not meaningful on negative earnings and cash flow.
Book-based valuation is more relevant here, with price-to-book at 3.52x and tangible book value per share at 6.90.
The balance sheet provides some downside support, with cash per share of 7.32 and net current asset value of 460.3M.
Risk Profile
The main risk remains persistent operating losses and negative cash generation despite a strong liquidity cushion.
Low leverage reduces financial distress risk, but weak profitability leaves the business dependent on continued cash reserves or future financing.
Valuation is difficult to anchor because earnings, EBITDA, and free cash flow are all negative.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Bicara Therapeutics Inc. Common Stock. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

